SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Conditions

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Trial Timeline

Feb 5, 2024 → Jul 1, 2026

NCT ID

NCT06122389

About SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide

SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06122389. Target conditions include Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06122389	Phase 3	Recruiting	Feb 5, 2024	Jul 1, 2026	Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

Competing Products

20 competing products in Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

See all competitors

Product	Company	Stage	Hype Score
agenT-797	MiNK Therapeutics	Phase 1	25
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Eribulin mesylate	Eisai	Phase 2	52
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41
ISB 1342	Glenmark Pharmaceuticals	Phase 1	33
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	52
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	33
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	33
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	41
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	33
AZD4573	AstraZeneca	Phase 2	52
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	23
Administration of AZD6738	AstraZeneca	Phase 1	33
Blinatumomab	Amgen	Phase 2	51

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved